Non-Small Cell Lung Cancer (NSCLC)

Findings from a previous phase 1/2a trial demonstrate that zipalertinib is a potential treatment option for pretreated patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

The fourth-generation tyrosine kinase inhibitor yields several partial responses and a tolerable safety profile in a small population of patients with EGFR-mutated non–small cell lung cancer in a phase 1 trial.

Confirmatory results from the phase 3 PAPILLON study further support the FDA approval of amivantamab-vmjw for patients with locally advanced/metastatic EGFR exon 20 insertion–mutant non–small cell lung cancer.

Findings from the phase 1b KRYSTAL-1 trial support the continued development of adagrasib in the treatment of patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Treatment with tepotinib and gefitinib appears to be beneficial compared with chemotherapy in a MET-amplified subgroup of patients with non–small cell lung cancer.

Datopotamab deruxtecan produces no new safety signals among patients with locally advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 trial.

A pair of experts explore the expanding treatment landscape in non–small cell lung cancer for patients with EGFR exon 20 insertion mutations.

An updated analysis from the phase 3 ADAURA trial reports no significant changes in osimertinib’s safety profile in non–small cell lung cancer since the primary analysis.

The accepted new drug application is for Pemrydi RTU, a ready-to-use injectable that requires no reconstitution, dilution, or refrigeration.

Approval of the Droplex EGFR Mutation Test v2 may improve access to appropriate targeted therapies for patients with EGFR-mutated non–small cell lung cancer in Korea.

Longitudinal ctDNA assessments may be a relevant tool for making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on findings from the phase 2 APPLE trial.

BL-B01D1 may produce promising antitumor activity in a heavily pretreated population of patients with EGFR-mutated non–small cell lung cancer, according to an expert at University Cancer Center in Guangzhou, China.

Sotorasib maintains a progression-free survival benefit compared with docetaxel in the treatment of patients with KRAS G12C-mutated non–small cell lung cancer in the phase 3 CodeBreaK 200 trial.

The results of the phase 3 LUNAR trial evaluating tumor treating fields plus standard-of-care therapies among patients with metastatic non–small cell lung cancer are “encouraging,” according to an expert from Winship Cancer Institute of Emory University.

Adding pembrolizumab to chemotherapy shows little increase in adverse effects among patients with metastatic nonsquamous non–small cell lung cancer in the phase 3 KEYNOTE-789 trial.

Sunvozertinib shows a similar safety profile to other EGFR tyrosine kinase inhibitors in the treatment of EGFR wild-type non–small cell lung cancer in the WO-KONH6 study.

Datopotamab deruxtecan plus pembrolizumab produces no new safety signals in the treatment of patients with advanced non–small cell lung cancer in the phase 1b TROPION-Lung02 trial.

Nivolumab plus ipilimumab and chemotherapy also appears to produce a higher overall response rate compared with chemotherapy alone among those with squamous non–small cell lung cancer in the phase 3 CheckMate 9LA trial.

Patients who receive nivolumab plus chemotherapy for non–small cell lung cancer may experience sustained improvement in time to death or distant metastasis, according to an expert from McGill University Health Center.

Rilvegostomig appears to yield no dose-limiting toxicities among patients with advanced or metastatic PD-L1–positive non–small cell lung cancer in the phase 1/2 ARTEMIDE-01 study.

ADAURA included patients at least 18 years of age with completely resected stage IB to IIIA nonsquamous NSCLC who harbored EGFR exon 19 deletions or exon 21 L858R mutations.

For patients with early-stage non–small cell lung cancer, the addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab as a monotherapy results in a significant improvement in event-free survival and pathological response.

The safety review committee of the phase 1/2 Acclaim-1 trial identifies a recommended phase 2 dose of quaratusugene ozeplasmid plus osimertinib in the management of advanced non–small cell lung cancer.

Data from the phase 3 CheckMate 816 trial support the European Medicines Agency’s Committee for Medicinal Products for Human Use recommendation to approve nivolumab plus platinum-based chemotherapy as a treatment for resectable non–small cell lung cancer.

Findings from the registrational phase 1/2 TRIDENT-1 trial support the new drug application for repotrectinib in the treatment of those with ROS1-positive advanced or metastatic non–small cell lung cancer.